Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965432 · ClinicalTrials.gov registry record · Phase 1
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
A Phase 1 study, sponsored by Seaside Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00965432: Completed Phase 1 study, sponsored by Seaside Therapeutics.
NCT00965432 is a Phase 1 study that has completed, run by Seaside Therapeutics. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965432, a Phase 1 study, has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension
Interventions
- DRUG STX107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00965432
The ClinicalTrials.gov registry entry for NCT00965432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STX107 is the first listed.
NCT00965432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00965432 about?
NCT00965432 is a clinical study titled "A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107". The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension
What is the current status of trial NCT00965432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00965432?
The interventions under investigation include: STX107 (DRUG).
Who is sponsoring clinical trial NCT00965432?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.